Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy
Purpose To retrospectively evaluate the clinical outcomes of cryoablation for secondary renal cell carcinoma for patients with a history of nephrectomy for initial renal cell carcinoma. Materials and Methods Thirty patients with 40 renal tumors who had undergone a nephrectomy for initial renal cell...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular and interventional radiology 2021-03, Vol.44 (3), p.414-420 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 420 |
|---|---|
| container_issue | 3 |
| container_start_page | 414 |
| container_title | Cardiovascular and interventional radiology |
| container_volume | 44 |
| creator | Ushijima, Yasuhiro Asayama, Yoshiki Nishie, Akihiro Takayama, Yukihisa Kubo, Yuichiro Ishimatsu, Keisuke Ishigami, Kousei |
| description | Purpose
To retrospectively evaluate the clinical outcomes of cryoablation for secondary renal cell carcinoma for patients with a history of nephrectomy for initial renal cell carcinoma.
Materials and Methods
Thirty patients with 40 renal tumors who had undergone a nephrectomy for initial renal cell carcinoma and cryoablation for renal cell carcinoma as a secondary treatment during the period from April 2014 to December 2018 at a single center institution were enrolled. The patients' overall survival, local control, relapse-free survival, change of renal function, and complications were evaluated. The clinical factors of relapse-free survival were also evaluated.
Results
The 5 year overall survival rate was 94.5%, the 5 year local control rate was 89.3%, and the 5 year relapse-free survival rate (RFSR) was 56.3%. There was an average reduction in renal function of 8.5% after 1 year, and > grade 3 complications occurred in only one case. The RFSR in the patients whose initial stage was T3 was 0%, significantly lower than the 70.4% RFSR in the patients whose initial stage was T1 or T2.
Conclusion
Cryoablation for secondary renal cell carcinoma after nephrectomy was safe and provided good local control with preserved renal function. However, the indications for cryoablation should be carefully considered for patients with T3-stage initial renal cell carcinoma, because of the high risk of relapse.
Level of evidence
III |
| doi_str_mv | 10.1007/s00270-020-02709-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2461863534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2461863534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-a982c52fc45c272bd0c50cfdb2bc812c4891934001f4d384ae2f97782ad640a63</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMoun78AQ9S8OKlOpkkbXqUxU9EwQ_wFtI0XSvbZk1alv33Zt1VwYOHJId55p3JQ8ghhVMKkJ8FAMwhBVyeHIp0vkFGlDNMQWavm2QENOcpFYLukN0Q3gGokCi2yQ5jCAILGJHbsV84XU5137guqZ1PnqxxXaX9Inm0nZ4mYzuNl_am6Vyrk_O6txEa_KQxsXpvZ2_emt61i32yVetpsAfrd4-8XF48j6_Tu4erm_H5XWpYgX2qC4lGYG24MJhjWYERYOqqxNJIiobLghaMx2VrXjHJtcW6yHOJuso46IztkZNV7sy7j8GGXrVNMHFL3Vk3BIU8ozJjgvGIHv9B393g46-WlMwyxIzTSOGKMt6F4G2tZr5powFFQS1Nq5VpFU2rL9NqHpuO1tFD2drqp-VbbQTYCgix1E2s_539T-wnOA6IKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486622641</pqid></control><display><type>article</type><title>Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy</title><source>SpringerLink Journals</source><creator>Ushijima, Yasuhiro ; Asayama, Yoshiki ; Nishie, Akihiro ; Takayama, Yukihisa ; Kubo, Yuichiro ; Ishimatsu, Keisuke ; Ishigami, Kousei</creator><creatorcontrib>Ushijima, Yasuhiro ; Asayama, Yoshiki ; Nishie, Akihiro ; Takayama, Yukihisa ; Kubo, Yuichiro ; Ishimatsu, Keisuke ; Ishigami, Kousei</creatorcontrib><description>Purpose
To retrospectively evaluate the clinical outcomes of cryoablation for secondary renal cell carcinoma for patients with a history of nephrectomy for initial renal cell carcinoma.
Materials and Methods
Thirty patients with 40 renal tumors who had undergone a nephrectomy for initial renal cell carcinoma and cryoablation for renal cell carcinoma as a secondary treatment during the period from April 2014 to December 2018 at a single center institution were enrolled. The patients' overall survival, local control, relapse-free survival, change of renal function, and complications were evaluated. The clinical factors of relapse-free survival were also evaluated.
Results
The 5 year overall survival rate was 94.5%, the 5 year local control rate was 89.3%, and the 5 year relapse-free survival rate (RFSR) was 56.3%. There was an average reduction in renal function of 8.5% after 1 year, and > grade 3 complications occurred in only one case. The RFSR in the patients whose initial stage was T3 was 0%, significantly lower than the 70.4% RFSR in the patients whose initial stage was T1 or T2.
Conclusion
Cryoablation for secondary renal cell carcinoma after nephrectomy was safe and provided good local control with preserved renal function. However, the indications for cryoablation should be carefully considered for patients with T3-stage initial renal cell carcinoma, because of the high risk of relapse.
Level of evidence
III</description><identifier>ISSN: 0174-1551</identifier><identifier>EISSN: 1432-086X</identifier><identifier>DOI: 10.1007/s00270-020-02709-w</identifier><identifier>PMID: 33205290</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cardiology ; Clinical Investigation ; Complications ; Imaging ; Interventional Oncology ; Kidney cancer ; Kidney stones ; Medicine ; Medicine & Public Health ; Nephrectomy ; Nuclear Medicine ; Patients ; Radiology ; Renal cell carcinoma ; Renal function ; Secondary treatment ; Survival ; Tumors ; Ultrasound</subject><ispartof>Cardiovascular and interventional radiology, 2021-03, Vol.44 (3), p.414-420</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c392t-a982c52fc45c272bd0c50cfdb2bc812c4891934001f4d384ae2f97782ad640a63</cites><orcidid>0000-0002-8340-6342</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00270-020-02709-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00270-020-02709-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33205290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ushijima, Yasuhiro</creatorcontrib><creatorcontrib>Asayama, Yoshiki</creatorcontrib><creatorcontrib>Nishie, Akihiro</creatorcontrib><creatorcontrib>Takayama, Yukihisa</creatorcontrib><creatorcontrib>Kubo, Yuichiro</creatorcontrib><creatorcontrib>Ishimatsu, Keisuke</creatorcontrib><creatorcontrib>Ishigami, Kousei</creatorcontrib><title>Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy</title><title>Cardiovascular and interventional radiology</title><addtitle>Cardiovasc Intervent Radiol</addtitle><addtitle>Cardiovasc Intervent Radiol</addtitle><description>Purpose
To retrospectively evaluate the clinical outcomes of cryoablation for secondary renal cell carcinoma for patients with a history of nephrectomy for initial renal cell carcinoma.
Materials and Methods
Thirty patients with 40 renal tumors who had undergone a nephrectomy for initial renal cell carcinoma and cryoablation for renal cell carcinoma as a secondary treatment during the period from April 2014 to December 2018 at a single center institution were enrolled. The patients' overall survival, local control, relapse-free survival, change of renal function, and complications were evaluated. The clinical factors of relapse-free survival were also evaluated.
Results
The 5 year overall survival rate was 94.5%, the 5 year local control rate was 89.3%, and the 5 year relapse-free survival rate (RFSR) was 56.3%. There was an average reduction in renal function of 8.5% after 1 year, and > grade 3 complications occurred in only one case. The RFSR in the patients whose initial stage was T3 was 0%, significantly lower than the 70.4% RFSR in the patients whose initial stage was T1 or T2.
Conclusion
Cryoablation for secondary renal cell carcinoma after nephrectomy was safe and provided good local control with preserved renal function. However, the indications for cryoablation should be carefully considered for patients with T3-stage initial renal cell carcinoma, because of the high risk of relapse.
Level of evidence
III</description><subject>Cardiology</subject><subject>Clinical Investigation</subject><subject>Complications</subject><subject>Imaging</subject><subject>Interventional Oncology</subject><subject>Kidney cancer</subject><subject>Kidney stones</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrectomy</subject><subject>Nuclear Medicine</subject><subject>Patients</subject><subject>Radiology</subject><subject>Renal cell carcinoma</subject><subject>Renal function</subject><subject>Secondary treatment</subject><subject>Survival</subject><subject>Tumors</subject><subject>Ultrasound</subject><issn>0174-1551</issn><issn>1432-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LxDAQhoMoun78AQ9S8OKlOpkkbXqUxU9EwQ_wFtI0XSvbZk1alv33Zt1VwYOHJId55p3JQ8ghhVMKkJ8FAMwhBVyeHIp0vkFGlDNMQWavm2QENOcpFYLukN0Q3gGokCi2yQ5jCAILGJHbsV84XU5137guqZ1PnqxxXaX9Inm0nZ4mYzuNl_am6Vyrk_O6txEa_KQxsXpvZ2_emt61i32yVetpsAfrd4-8XF48j6_Tu4erm_H5XWpYgX2qC4lGYG24MJhjWYERYOqqxNJIiobLghaMx2VrXjHJtcW6yHOJuso46IztkZNV7sy7j8GGXrVNMHFL3Vk3BIU8ozJjgvGIHv9B393g46-WlMwyxIzTSOGKMt6F4G2tZr5powFFQS1Nq5VpFU2rL9NqHpuO1tFD2drqp-VbbQTYCgix1E2s_539T-wnOA6IKQ</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Ushijima, Yasuhiro</creator><creator>Asayama, Yoshiki</creator><creator>Nishie, Akihiro</creator><creator>Takayama, Yukihisa</creator><creator>Kubo, Yuichiro</creator><creator>Ishimatsu, Keisuke</creator><creator>Ishigami, Kousei</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8340-6342</orcidid></search><sort><creationdate>20210301</creationdate><title>Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy</title><author>Ushijima, Yasuhiro ; Asayama, Yoshiki ; Nishie, Akihiro ; Takayama, Yukihisa ; Kubo, Yuichiro ; Ishimatsu, Keisuke ; Ishigami, Kousei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-a982c52fc45c272bd0c50cfdb2bc812c4891934001f4d384ae2f97782ad640a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cardiology</topic><topic>Clinical Investigation</topic><topic>Complications</topic><topic>Imaging</topic><topic>Interventional Oncology</topic><topic>Kidney cancer</topic><topic>Kidney stones</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrectomy</topic><topic>Nuclear Medicine</topic><topic>Patients</topic><topic>Radiology</topic><topic>Renal cell carcinoma</topic><topic>Renal function</topic><topic>Secondary treatment</topic><topic>Survival</topic><topic>Tumors</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ushijima, Yasuhiro</creatorcontrib><creatorcontrib>Asayama, Yoshiki</creatorcontrib><creatorcontrib>Nishie, Akihiro</creatorcontrib><creatorcontrib>Takayama, Yukihisa</creatorcontrib><creatorcontrib>Kubo, Yuichiro</creatorcontrib><creatorcontrib>Ishimatsu, Keisuke</creatorcontrib><creatorcontrib>Ishigami, Kousei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular and interventional radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ushijima, Yasuhiro</au><au>Asayama, Yoshiki</au><au>Nishie, Akihiro</au><au>Takayama, Yukihisa</au><au>Kubo, Yuichiro</au><au>Ishimatsu, Keisuke</au><au>Ishigami, Kousei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy</atitle><jtitle>Cardiovascular and interventional radiology</jtitle><stitle>Cardiovasc Intervent Radiol</stitle><addtitle>Cardiovasc Intervent Radiol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>44</volume><issue>3</issue><spage>414</spage><epage>420</epage><pages>414-420</pages><issn>0174-1551</issn><eissn>1432-086X</eissn><abstract>Purpose
To retrospectively evaluate the clinical outcomes of cryoablation for secondary renal cell carcinoma for patients with a history of nephrectomy for initial renal cell carcinoma.
Materials and Methods
Thirty patients with 40 renal tumors who had undergone a nephrectomy for initial renal cell carcinoma and cryoablation for renal cell carcinoma as a secondary treatment during the period from April 2014 to December 2018 at a single center institution were enrolled. The patients' overall survival, local control, relapse-free survival, change of renal function, and complications were evaluated. The clinical factors of relapse-free survival were also evaluated.
Results
The 5 year overall survival rate was 94.5%, the 5 year local control rate was 89.3%, and the 5 year relapse-free survival rate (RFSR) was 56.3%. There was an average reduction in renal function of 8.5% after 1 year, and > grade 3 complications occurred in only one case. The RFSR in the patients whose initial stage was T3 was 0%, significantly lower than the 70.4% RFSR in the patients whose initial stage was T1 or T2.
Conclusion
Cryoablation for secondary renal cell carcinoma after nephrectomy was safe and provided good local control with preserved renal function. However, the indications for cryoablation should be carefully considered for patients with T3-stage initial renal cell carcinoma, because of the high risk of relapse.
Level of evidence
III</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33205290</pmid><doi>10.1007/s00270-020-02709-w</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8340-6342</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0174-1551 |
| ispartof | Cardiovascular and interventional radiology, 2021-03, Vol.44 (3), p.414-420 |
| issn | 0174-1551 1432-086X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2461863534 |
| source | SpringerLink Journals |
| subjects | Cardiology Clinical Investigation Complications Imaging Interventional Oncology Kidney cancer Kidney stones Medicine Medicine & Public Health Nephrectomy Nuclear Medicine Patients Radiology Renal cell carcinoma Renal function Secondary treatment Survival Tumors Ultrasound |
| title | Cryoablation for Secondary Renal Cell Carcinoma After Surgical Nephrectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A18%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cryoablation%20for%20Secondary%20Renal%20Cell%20Carcinoma%20After%20Surgical%20Nephrectomy&rft.jtitle=Cardiovascular%20and%20interventional%20radiology&rft.au=Ushijima,%20Yasuhiro&rft.date=2021-03-01&rft.volume=44&rft.issue=3&rft.spage=414&rft.epage=420&rft.pages=414-420&rft.issn=0174-1551&rft.eissn=1432-086X&rft_id=info:doi/10.1007/s00270-020-02709-w&rft_dat=%3Cproquest_cross%3E2461863534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2486622641&rft_id=info:pmid/33205290&rfr_iscdi=true |